Athira Pharma, Inc. (ATHA)
NASDAQ (CM) NASDAQ (CM) Primary Summary
ATHA Chart
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript
Athira Pharma, Inc. (ATHA) Discusses Acquisition of Rights to Lasofoxifene Phase III Program for Metastatic Breast Cancer Transcript
ATHA Energy expands uranium potential at Angilak
ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) revealed that a survey at its Angilak uranium project in Nunavut has expanded the known depth of uranium mineralization at the Lac 50 Deposit to over one kilometer. The survey also identified a new 25-kilometer conductive trend along the western margin of the Angikuni Basin, according to a statement from ATHA.
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct
Seattle-area biotech company Athira Pharma agreed to pay $4.
Athira Pharma, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RJ Rebecca Judd Pathstone Holdings, LLC | 38,606 | $159,829 | $159,828.84 | -$0.16 | - |
 Ian Jameson American Capital Advisory, LLC | 200 | $828 | $828 | - | - |
Athira Pharma, Inc. (ATHA) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Athira Pharma, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mark J. Litton CEO | NASDAQ (CM) Exchange | 04746L203 CUSIP |
| US Country | 26 Employees | - Last Dividend | 18 Sep 2025 Last Split | 18 Sep 2020 IPO Date |
Overview
Athira Pharma, Inc., initially known as M3 Biotechnology, Inc. before its name change in April 2019, stands out as a late clinical-stage biopharmaceutical entity engaged in the development of small molecule therapies aimed at restoring neuronal health and mitigating neurodegeneration. With its inception in 2011, the company has set up its headquarters in Bothell, Washington, marking its commitment to tackling some of the most challenging neurodegenerative disorders. Athira Pharma targets diseases such as Alzheimer's, Parkinson's disease dementia, and Dementia with Lewy bodies through innovative approaches to modulate the neurotrophic hepatocyte growth factor (HGF) system and its MET receptor, focusing on achieving a healthy nervous system. Furthermore, its engagement in significant collaboration and a grant agreement with the National Institutes of Health Grant for the ACT-AD Phase 2 clinical trial of fosgonimeton demonstrates Athira Pharma's dedication to leveraging partnerships and funding opportunities to advance its clinical programs.
Products and Services
- Fosgonimeton (ATH-1017)
This lead product candidate is a cornerstone of Athira Pharma's developmental efforts. It is a small molecule aimed at modulating the HGF/MET system to support a healthy nervous system. Fosgonimeton is currently undergoing LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for treating Alzheimer's disease. Additionally, it is in Phase 2 clinical trials targeting Parkinson's disease dementia and Dementia with Lewy bodies, showcasing its potential to address a broad spectrum of neurodegenerative diseases.
- ATH-1020
ATH-1020 represents another significant endeavor by Athira Pharma, manifesting as an orally available, brain-penetrant small molecule designed to boost the HGF/MET system. Currently in Phase 1 clinical trials, ATH-1020's primary focus is on treating neuropathic pain and neurodegenerative diseases, indicating the company's commitment to exploring new therapeutic avenues within the neurodegenerative disease domain.
- ATH-1105
Positioned as a potential game-changer for conditions like Amyotrophic Lateral Sclerosis (ALS), ATH-1105 is an oral small molecule drug candidate in preclinical development. As Athira Pharma aims to translate its preclinical successes into clinical advancements, ATH-1105 underscores the company's dedication to diversifying its pipeline across various stages of neurodegenerative disease progression.
- License Agreement with Washington State University
Underpinning Athira Pharma's product development strategy is a pivotal license agreement with Washington State University. This agreement grants Athira Pharma the rights to develop and sell products covered by certain licensed patents, including dihexa, a chemical compound into which fosgonimeton converts post-administration. This strategic partnership not only accelerates the commercialization path for Athira Pharma's leading compounds but also strengthens its intellectual property portfolio and market position.
